Merck Suvorexant Scheduled, But DEA Delays Remain an Issue
This article was originally published in RPM Report
Executive Summary
DEA scheduled Merck’s Belsomra (suvorexant) August 28, only two weeks after its August 13 approval – much faster than the year-long wait for some drugs. But don’t take that to mean that the DEA process is moving faster for new drugs.
You may also be interested in...
Idorsia Requests DEA Lift Controlled Substance Restrictions On Dual Orexin Receptor Antagonists For Insomnia
Schedule IV classification for Idorsia’s Quviviq, along with Merck & Co’s Belsomra and Eisai’s Dayvigo, distorts the drug class’ benefit-risk profile relative to other insomnia treatments, which are prioritized for prescribing but carry higher risk of abuse and other adverse events, company says.
DEA Delays in Scheduling Are Offsetting FDA’s Improved Decision Making
FDA is showing a renewed commitment to meeting review deadlines for new molecular entities, but that is not translating into earlier commercial availability for all NMEs. Some products also need a controlled substance scheduling decision from the Drug Enforcement Administration; those actions have become a new regulatory purgatory that can be painful and frustrating.
Drug Shortage Could Be Addressed By ‘Resilience Rating’ From Private Entity Under HHS Plan
US HHS is proposing a public-private partnership to assign ratings to manufacturers based on quality/resilience of supply, tied to a purchasing incentive program for providers. The non-agency approach may be key to overcoming industry and political objections.